Kronik karaciğer fibrozunda sistemik immün yanıtın yönlendirilmesi
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
İnönü Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Kronik Karaciğer Fibrozunda Sistemik İmmün Yanıtın Yönlendirilmesi Amaç: Mevcut çalışmanın amacı deneysel kronik karaciğer fibrozu oluşturulan deneklerde immünizasyon sonrası oluşan zayıf özgül antikor yanıtının, tetanoz toksoidi ile immün stimülasyon sonucu arttırılabilmesinin araştırılmasıdır. Materyal ve Metod: Tiyoasetamid (TAA) ile uyarılarak karaciğer fibroz modeli oluşturulmuş BALB/c türü deney farelerine Engerix™ hepatit B aşısı ve Tetavax tetanoz toksoidi intramüsküler yoldan verilmiştir. Gruplara ait deneklerin serum örneklerinde karaciğer enzim düzeyleri ve Anti-HBs düzeylerinin ölçümleri, karaciğer doku örneklerinde ise histopatolojik değerlendirmeler gerçekleştirilmiştir. Bulgular: Mevcut çalışmada TAA ile oluşturulan karaciğer fibrozunda karaciğer fonksiyon enzimlerinden AST, ALT, AP enzimlerine ait serum konsantrasyonlarında belirgin düzeyde artış görülmüştür. TAA + Hepatit B aşı grubunda serum AST, AP düzeyindeki azalma anlamsız, ALT düzeyindeki azalma anlamlı bulunmuştur. Deneklerin canlı vücut ağırlığı / karaciğer ağırlığı oranında kontrol grubu ile Hepatit B aşısı grubu arasında anlamlı farklılık görülmezken; TAA, TAA + Hepatit B aşısı, TAA + Hepatit B aşısı + Tetavax tetanoz toksoid gruplarında bu oranda görülen belirgin azalma saptanmıştır. Çalışmada fibroz oluşturulan deneklere uygulanan hepatit B aşısı sonrası ölçülen Anti-HBs düzeyi sadece hepatit B aşısı uygulanan deneklere göre belirgin düzeyde düşük saptanmıştır. TAA + Hepatit B aşısı + Tetanoz toksoidi uygulanan grupta ise TAA + Hepatit B aşısı grubuna göre Anti-HBs düzeyinde istatistiksel olarak anlamlı bir artış tespit edilmiştir. Sonuç: Kronik karaciğer fibrozunda immünizasyon sonrası zayıf özgül antikor yanıtı oluşmakta ve bu yanıt bir immün stimülatör olan tetanoz toksoidi kullanılarak arttırılabilmektedir.
Management Of Systemıc Immune Response In Chronıc Lıver Fıbrosıs Aim: The aim of the study is to investigate the ability of the subjects with experimental chronic liver fibrosis to develop a weak specific antibody response after immunization as a result of immune stimulation with tetanus toxoid. Materials and Methods: The subjects with BALB / c type of hepatocytes were injected with TAA and the Engerix™ hepatitis B vaccine and Tetavax tetanus toxoid were administered intramuscularly. Liver enzyme levels and anti-HBs levels were measured in the serum samples of the subjects and histopathological evaluations were made in liver tissue samples. Results: In the study, serum concentrations of AST, ALT and AP enzymes were significantly increased in liver fibrosis induced by TAA. In the TAA + Hepatitis B vaccine group, the decrease in serum AST, AP level was insignificant and the decrease in ALT level was found to be significant. There was no significant difference between the control group and the hepatitis B vaccine group in terms of body weight / liver weight. The significant decrease in TAA, TAA + Hepatitis B vaccine, TAA + Hepatitis B vaccine + Tetavax tetanus toxoid groups was found to be statistically significant. When the anti-HBs levels of the control group and the hepatitis B vaccine group were compared, a significant increase was detected in the hepatitis B vaccine group. In the study, the level of Anti-HBs measured after hepatitis B vaccine was significantly lower in subjects with fibrosis than the subjects who received hepatitis B vaccine. In TAA + Hepatitis B vaccine + Tetavax tetanus toxoid group, there was a statistically significant increase in Anti-HBs level according to TAA + Hepatitis B vaccine group. Conclusion: In chronic liver fibrosis, it produces a weak specific antibody response after immunization and this response can be increased by using an immunostimulator, tetanus toxoid.
Management Of Systemıc Immune Response In Chronıc Lıver Fıbrosıs Aim: The aim of the study is to investigate the ability of the subjects with experimental chronic liver fibrosis to develop a weak specific antibody response after immunization as a result of immune stimulation with tetanus toxoid. Materials and Methods: The subjects with BALB / c type of hepatocytes were injected with TAA and the Engerix™ hepatitis B vaccine and Tetavax tetanus toxoid were administered intramuscularly. Liver enzyme levels and anti-HBs levels were measured in the serum samples of the subjects and histopathological evaluations were made in liver tissue samples. Results: In the study, serum concentrations of AST, ALT and AP enzymes were significantly increased in liver fibrosis induced by TAA. In the TAA + Hepatitis B vaccine group, the decrease in serum AST, AP level was insignificant and the decrease in ALT level was found to be significant. There was no significant difference between the control group and the hepatitis B vaccine group in terms of body weight / liver weight. The significant decrease in TAA, TAA + Hepatitis B vaccine, TAA + Hepatitis B vaccine + Tetavax tetanus toxoid groups was found to be statistically significant. When the anti-HBs levels of the control group and the hepatitis B vaccine group were compared, a significant increase was detected in the hepatitis B vaccine group. In the study, the level of Anti-HBs measured after hepatitis B vaccine was significantly lower in subjects with fibrosis than the subjects who received hepatitis B vaccine. In TAA + Hepatitis B vaccine + Tetavax tetanus toxoid group, there was a statistically significant increase in Anti-HBs level according to TAA + Hepatitis B vaccine group. Conclusion: In chronic liver fibrosis, it produces a weak specific antibody response after immunization and this response can be increased by using an immunostimulator, tetanus toxoid.
Açıklama
Anahtar Kelimeler
Tıbbi Biyoloji, Medical Biology
